Inhibrx Reported Updated Trial Results for Cancer Drug
The study of INBRX-106 combined with pembrolizumab showed improved outcomes for head and neck cancer patients.
Updated on Oct. 4, 2026 in Cancer
Live Poll
Should the FDA accelerate approval for new cancer treatments based on early-stage clinical trial data?
On September 8, 2026, Inhibrx announced updated phase 2 trial data for INBRX-106 paired with pembrolizumab in patients with head and neck squamous cell carcinoma. The combination therapy significantly outperformed pembrolizumab monotherapy across key survival and response metrics.
Why it matters
By demonstrating higher response rates and longer progression-free survival, Inhibrx aims to leverage these results to support a potential accelerated approval pathway. This expansion seeks to address treatment gaps for patients with advanced disease.
The combination therapy reached a 9.6-month median progression-free survival compared to 4.9 months for monotherapy. These results were drawn from a study of 63 evaluable patients with PD-L1 expression scores of 20 or greater.
The players
Inhibrx
This biotechnology company focuses on developing therapeutic protein candidates for various diseases, including oncology.
The details
Patients in the combination arm received intravenous INBRX-106 alongside 200 mg of pembrolizumab every 3 weeks, showing notable efficacy in HPV-positive subgroups with an 80% response rate. While the treatment showed promise, common adverse effects reported by trial participants included rash, fatigue, and diarrhea.
Timeline
May 2026: Interim study data was reported.
August 19, 2026: Data cutoff for the efficacy analysis occurred.
September 8, 2026: Inhibrx released the study results.
May 2029: The trial is estimated to be completed.
The Big Picture
This study operates within the standards set by the PD-L1 expression combined positive score clinical threshold to determine trial eligibility. The trial follows established industry patterns by focusing its enrollment on patients who meet these specific PD-L1 expression benchmarks.
The trial results suggest that eligible patients with high PD-L1 expression may soon have access to an enhanced immunotherapy option if regulatory pathways proceed. Patients should consult their oncologists to understand how these findings might influence future treatment eligibility.
The takeaway
These findings highlight the potential for combining novel therapeutics with existing immune checkpoint inhibitors to improve patient outcomes in head and neck cancer. Continued monitoring of safety profiles and survival data will be critical as the company moves toward phase 3 testing.
What happens next
Inhibrx plans to expand the current trial by 50 additional patients and subsequently initiate a phase 3 confirmatory study to build on the reported results.
Further reading
For broader information on clinical research and oncology treatments, explore the Cancer section.
More information
Review the full details of the study on the clinical trial registration page.
Source note: This article includes information reported by OncLive.
Live Poll
Should the FDA accelerate approval for new cancer treatments based on early-stage clinical trial data?
